SEC Form 4
Scribe Therapeutics Inc. (SCTX) insider trading
In the 12 months to Nov 19, 2026, 6 SCTX insiders reported open-market purchases of $71.3M across 6 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $71.3M
- 6 filings
Who traded SCTX, and when
- Purchase
SCTX daily close from Jul 24, 2026 to Nov 18, 2026, between $14.05 and $37.25, last $14.05. 0 sale and 6 purchase filings by 6 insiders, marked at their filing dates. Behzad Aghazadeh, Director: bought $36.3M across 1 filing, first filed Jul 28, 2026, last Jul 28, 2026. Carl L. Gordon, Director: bought $15.0M across 1 filing, first filed Jul 29, 2026, last Jul 29, 2026. OrbiMed Capital GP VIII LLC, Director: bought $15.0M across 1 filing, first filed Jul 29, 2026, last Jul 29, 2026. Benjamin A. Horowitz, 10% owner: bought $5.0M across 1 filing, first filed Jul 29, 2026, last Jul 29, 2026. Svetlana Lucas, Chief Business Officer: bought $45.0K across 1 filing, first filed Jul 27, 2026, last Jul 27, 2026. David Parrot, Chief Financial Officer: bought $40.0K across 1 filing, first filed Jul 27, 2026, last Jul 27, 2026.
Largest mark · tap a row for others
Behzad Aghazadeh · Director
Purchase $36,259,761
2,391,238 shares at $15.16 avg
Filed Jul 28, 2026 · traded Jul 24
Close on filing date $18.06
Behzad Aghazadeh · Director
Director
$36.3M boughtCarl L. Gordon · Director
Director
$15.0M boughtOrbiMed Capital GP VIII LLC · Director
Director
$15.0M boughtBenjamin A. Horowitz · 10% owner
10% owner
$5.0M boughtSvetlana Lucas · Chief Business Officer
Chief Business Officer
$45.0K boughtDavid Parrot · Chief Financial Officer
Chief Financial Officer
$40.0K boughtOpen-market trades
6 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Behzad Aghazadeh | Director | — | $36.3M | 1 | — | |
| Carl L. Gordon | Director | — | $15.0M | 1 | — | |
| OrbiMed Capital GP VIII LLC | Director | — | $15.0M | 1 | — | |
| Benjamin A. Horowitz | 10% owner | — | $5.0M | 1 | — | |
| Svetlana Lucas | Chief Business Officer | — | $45.0K | 1 | — | |
| David Parrot | Chief Financial Officer | — | $40.0K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | OrbiMed Capital GP VIII LLC Director | Purchase | 1,000,000 | $15.00 | $15.0M | 1,348,825 | |
traded | Carl L. Gordon Director | Purchase | 1,000,000 | $15.00 | $15.0M | 1,348,825 | |
traded | Benjamin A. Horowitz 10% owner | Purchase | 333,333 | $15.00 | $5.0M | 2,385,075 | |
traded | Behzad Aghazadeh Director | Purchase | 2,391,238 | $15.16 | $36.3M | 3,088,888 | |
traded | Svetlana Lucas Chief Business Officer | Purchase | 3,000 | $15.00 | $45.0K | 3,000 | |
traded | David Parrot Chief Financial Officer | Purchase | 2,666 | $15.00 | $40.0K | Multiple accounts |
GET /stocks/filings/vX/form-4?tickers=SCTX&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"SCTX"
],
"issuer_cik": "0001853921",
"owner_cik": "0001282930",
"accession_number": "0000947871-26-000734",
"form_type": "4",
"filing_date": "2026-07-29",
"period_of_report": "2026-07-23",
"issuer_name": "Scribe Therapeutics, Inc.",
"issuer_trading_symbol": "SCTX",
"owner_name": "GORDON CARL L",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-07-27",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1000000,
"transaction_price_per_share": 15,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 1348825,
"transaction_value": 15000000,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnotes",
"footnotes": [
{
"id": "F2",
"description": "Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."
},
{
"id": "F3",
"description": "The shares are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."
},
{
"id": "F4",
"description": "Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."
}
]
},
{
"tickers": [
"SCTX"
],
"issuer_cik": "0001853921",
"owner_cik": "0001845804",
"accession_number": "0000947871-26-000733",
"form_type": "4",
"filing_date": "2026-07-29",
"period_of_report": "2026-07-27",
"issuer_name": "Scribe Therapeutics, Inc.",
"issuer_trading_symbol": "SCTX",
"owner_name": "OrbiMed Capital GP VIII LLC",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-07-27",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1000000,
"transaction_price_per_share": 15,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 1348825,
"transaction_value": 15000000,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnotes",
"footnotes": [
{
"id": "F2",
"description": "Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."
},
{
"id": "F3",
"description": "The shares are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."
},
{
"id": "F4",
"description": "This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 5 records
- Other5 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Scribe Therapeutics Inc.'s CEO sold stock?
No. Benjamin L. Oakes (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is SCTX’s insider data?
These are SCTX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track SCTX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for SCTX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.